Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT06338384
Starting soon Observational

Examining Engagement Trends Among Participants in Peripheral Neuropathy Clinical Research

NCT06338384 · tracked via the Priya Life Science USA tracker
Sponsor
Power Life Sciences Inc
Phase
Observational
Started
2025-04
Last updated
2024-03-29

Condition(s) studied

Peripheral Neuropathy

Study summary

This trial aims to uncover the factors driving patient decisions regarding enrollment, withdrawal, or re-engagement in peripheral neuropathy clinical trials. Understanding these factors will significantly improve the relevance and effectiveness of future research endeavors.

Ultimately, this trial endeavors to deepen our understanding of the factors impacting peripheral neuropathy clinical trial participation. Enhancing participation rates could accelerate the development of innovative treatments for this debilitating condition.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Aged ≥ 18 years old * Diagnosis of peripheral neuropathy * Able to comprehend the investigational nature of the protocol and provide informed consent Exclusion Criteria: * Female patients who are currently pregnant or nursing * Inability to perform regular electronic reporting * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial

Primary outcome measure(s)

  • Number of peripheral neuropathy patients who decide to enroll in a clinical research — 3 months
  • Rate of peripheral neuropathy patients who remain in clinical trial to trial completion — 12 months

Trial sites (1)

FacilityCityRegionStatus
Power Life Sciences San Francisco California

More Power Life Sciences Inc. trials in the USA

Delving Into Participation Trends of Scleroderma Clinical Trials Starting soon
Investigating Participation Patterns Among Stage IV Melanoma Patients Starting soon
A Journey Into Participation Patterns Among Patients With Hidradenitis Suppurativa Starting soon
Exploring Clinical Study Experiences of People With Anorexia Nervosa Starting soon
Studying Patterns in Patient Engagement Among Treatment Resistant Depression Patients Starting soon

Other trials for the same condition

Clinical Study of a Micro-Implantable Pulse Generator for the Treatment of Peripheral Neuropathic Pain (COMFORT 2) Active, not recruiting
A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J Active, not recruiting
A Mixed-Methods Exploratory Pilot Study of the Investigational MYNERVA Leia Sensory Prosthesis in U.S. Adults With Peripheral Neuropathy Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06338384 on ClinicalTrials.gov ↗ ← All trials in the USA